Lineage Cell Therapeutics Files 8-K on Corporate Governance
Ticker: LCTX · Form: 8-K · Filed: Jul 2, 2025 · CIK: 876343
| Field | Detail |
|---|---|
| Company | Lineage Cell Therapeutics, Inc. (LCTX) |
| Form Type | 8-K |
| Filed Date | Jul 2, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, management-change, filing
TL;DR
Lineage Cell Therapeutics filed an 8-K detailing leadership changes and governance updates.
AI Summary
Lineage Cell Therapeutics, Inc. filed an 8-K on June 26, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. The filing also covers the submission of matters to a vote of security holders and includes financial statements and exhibits. The company, formerly known as BIOTIME INC, is incorporated in California and headquartered in Carlsbad.
Why It Matters
This 8-K filing provides crucial updates on Lineage Cell Therapeutics' corporate governance, including changes in leadership and board composition, which can impact strategic direction and investor confidence.
Risk Assessment
Risk Level: low — This filing primarily concerns corporate governance and administrative matters, with no immediate indication of significant financial or operational risks.
Key Players & Entities
- Lineage Cell Therapeutics, Inc. (company) — Registrant
- BIOTIME INC (company) — Former company name
- California (location) — State of Incorporation
- Carlsbad (location) — Principal Executive Offices City
FAQ
What specific items were reported under the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' section?
The filing indicates that these corporate governance matters were reported, but the specific details of departures, elections, appointments, or compensatory arrangements are not provided in this summary.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is June 26, 2025.
What is the Commission File Number for Lineage Cell Therapeutics, Inc.?
The Commission File Number for Lineage Cell Therapeutics, Inc. is 001-12830.
When did Lineage Cell Therapeutics, Inc. change its name from BIOTIME INC?
The date of the name change from BIOTIME INC was March 28, 1993.
What is the Standard Industrial Classification (SIC) code for Lineage Cell Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Lineage Cell Therapeutics, Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 2, 2025 regarding Lineage Cell Therapeutics, Inc. (LCTX).